Synthetic peptide studied as a dual agonist at the GIP and GLP-1 receptors, investigated in incretin and metabolic-signaling research.
Wholesale or institutional quantities? Request a custom quote — we'll follow up to discuss.
Every batch is independently tested before it's listed — no exceptions.
Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate both the GIP and GLP-1 receptors — the two primary incretin hormones the gut releases after eating to stimulate insulin secretion. Research shows the two receptors act synergistically: co-activating both produces a significantly larger insulin response than activating either alone. A fatty diacid chain attached to the peptide backbone extends its half-life, supporting once-weekly dosing in the clinical studies that led to its approval. Across the SURPASS clinical trial program, tirzepatide outperformed selective GLP-1-receptor agonists on both glycemic control and weight-related endpoints, and it's since become one of the most widely referenced dual-incretin agonists in metabolic research.
Purity results across recent lots — consistency you can check.
No reviews yet. Verified buyers can leave a review from their account once an order is completed.